Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment
Yue Zhang,Xue Han,Ke Wang,Da Liu,Xiaoyun Ding,Zhiqiang Hu,Jing Wang
DOI: https://doi.org/10.2147/IJN.S418100
IF: 7.033
2023-08-01
International Journal of Nanomedicine
Abstract:Yue Zhang, 1, &ast Xue Han, 1, &ast Ke Wang, 1 Da Liu, 1 Xiaoyun Ding, 2 Zhiqiang Hu, 2 Jing Wang 1, 3 1 School of Pharmacy, Ningxia Medical University, Yinchuan, 750004, People's Republic of China; 2 Oncology Hospital, General Hospital of Ningxia Medical University, Yinchuan, 750004, People's Republic of China; 3 Key Laboratory of Ningxia Minority Medicine Modernization, Ministry of Education, Yinchuan, 750004, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zhiqiang Hu, Oncology Hospital, General Hospital of Ningxia Medical University, 804 Shengli Street, Yinchuan, 750004, People's Republic of China, Tel/Fax +86 951 674 3771, Email Jing Wang, School of Pharmacy, Ningxia Medical University, 1160 Shengli Street, Yinchuan, 750004, People's Republic of China, Tel/Fax +86 951 408 1046, Email Purpose: Immune checkpoint inhibitors (ICI) have received the most attention for triple negative breast cancer (TNBC), while the response rate to ICI remains limited due to insufficient T cell infiltration. It is therefore essential that alternative strategies are developed to improve the therapeutic outcomes of ICI in non-responsive TNBC cases. The efficacy of pH-responsive nanomicelles (P/A/) co-loaded with paclitaxel (PTX), CXCR4 antagonist AMD3100, and PD-1/PD-L1 inhibitor BMS-1 activating the T cell-mediated antitumor immune response were evaluated using a 4T1 antiPD-1-resistance breast tumor model. Methods: In vitro, pH-responsive antitumor effect of P/A/ was investigated by assessing cell viability, migration and invasion. In vivo, the distribution of P/A/ was visualized in 4T1 orthotopic TNBC model using an IVIS spectrum imaging instrument. The efficacy of the co-delivery nanocarriers was evaluated by monitoring mouse survival, tumor growth and metastasis, cancer-associated fibroblasts (CAFs)-mediated tumor stroma and immunosuppressive microenvironment components, and the recruitment and infiltration of CD8 + T cells. Results: The prepared P/A/ in acid microenvironment demonstrates remarkable cytotoxicity against MDA-MB-231 cells, with an IC 50 of 105 μg/mL. Additionally, it exhibits substantial inhibition of tumor cell migration and invasion. The P/A/ based on co-delivery nanocarriers efficiently accumulate at the tumor site and release the drugs in a pH-responsive controlled manner. The nanomedicine-PTX, AMD3100, and BMS-1 formulation significantly inhibits tumor growth and lung/liver metastasis by inducing antitumor immune responses via CXCL12/CXCR4 axis blockade, and immunogenic cell death to reprogramme both tumor stroma and immunosuppressive microenvironment. As a result, CD8 + T cell infiltration is triggered into the tumor site, boosting the efficacy of ICI therapy synergistically. Conclusion: These results demonstrate that combination therapy using P/A/ reshapes CAFs-mediated tumor stroma and immunosuppressive microenvironment, which can enhance the infiltration of CD8 + T cells, thereby reactivating anti-tumor immunity for non-responsive TNBC cases. Keywords: TNBC, immunotherapy, co-delivery nanomicelles, CAFs, immunosuppressive microenvironment Triple negative breast cancer (TNBC), the most aggressive subtype of breast cancer, is characterized by high intratumoral heterogeneity, a lack of established molecular targets, low overall survival rates, and high recurrence rates. 1 While some metastatic TNBC patients have experienced clinical benefits from programmed cell death-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) inhibitors through the innovation of T cell-mediated immunotherapies, the overall response rate to immune checkpoint inhibitors (ICI) remains limited due to lack of known biomarkers, insufficient T cell infiltration, the immunosuppressive tumor microenvironment, and innate and acquired drug resistance. 2,3 These limitations motivate the development of new or alternative strategies to improve the therapeutic outcomes of ICI in non-responsive TNBC cases. Substantial evidence has established that the tumor microenvironment (TME) is a self-regulating ecosystem, where tumor cells, stromal cells, tumor vasculature, and immune cells are interwoven with noncellular components. This TME not only drives tumor progression but also profoundly alter the therapeutic response of tumors to ICI. 4,5 Currently, it is widely believed that the stromal matrix and suppressive immunocellular composition are the two primary factors causing immunosuppression in solid tumors. 5,6 In invasive human breast cancer, CXCL12 secreted by cancer-associated fibro -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology